APIQUEST USA CORPORATION

WORLD PERSPECTIVE

IMPORTANCE OF MEDICINAL PLANTS IN PRIMARY HEALTH CARE

 According to World Health Organization (WHO) a vast majority of people (about 80%) in the developing world relies on herbal medicines for their primary healthcare needs. There are 89 plant-derived drugs currently prescribed in the industrialized world. 

MAJOR DILEMMA

PARADIGM SHIFT 

Today, the world-wide health market is undergoing a product repolarization. 8 Million people are hospitalized each year for the ailments caused by the ingestion and side effects of prescription drugs. People are buying fewer pharmaceutical drugs and more health foods, preventive herbs and vitamins. Good herbal products have tendency to make people sick less often. 

GAME CHANGER

The World Health Organization (WHO) said it was encouraging research into natural medicines in Africa against Covid-19 and other epidemics. EXPERTS from WHO and two other organizations have "approved a protocol for Phase 3 herbal medicine clinical trials for Covid-19," 

 

          THE SOLUTION

More acceptance for the phytotherapy. Use of biotechnology and genetic engineering for the production of plant-based medicines (Cell culture, targeted biosynthesis, etc.). Demand of plant-based medicines for age-related disease (autoimmune, and degenerative diseases). Preventive medicines (antioxidants, vaccines, nutritional therapy, etc.) will be more important. Many new diseases among the poorest due to microbial resistance and water shortage. 

About us

OUR GOAL

APIQUEST-USA is a Delaware Corporation focused on solutions to  eradicate the deadly COVID-19 pandemic and allow the USA and the world to go back to business as usual. To date, the virus has claimed over 500,000 US lives and more than 2,500,000 worldwide. APIQUEST-USA signed an exclusive agreement with Dr. Valentin Agon, a renowned African doctor and researcher, owner of APIVIRINE. This natural antiviral drug has proven to be useful with lots of deadly viruses, including COVID-19 and HIV-AIDS.  

  

 

THE OPPORTINUTY

THE STATISTIC

Over 25,000 flowering plants in the World, less than 2 percent, have been exhaustively studied for their potential pharmacological activities and bioactive chemical constituents.  

Governments in developed countries, especially in Europe, have also been quick to consider the growing demand for herbal medicine and have funded significant research efforts to enhance the precision and sophistication of the area. It is likely to be a substantial driver for the Herbal Medicine Market over the forecast period. Government-funded clinical research facilities could provide a sophisticated, polished version of herbal medicine. Providing the customer with the best of both worlds, APIVIRINE fits in this category of medicinal plants. Africa’s pharmaceutical industry jumped to $20.8 billion in 2013 from just $4.7 billion a decade earlier. 

By 2026, the pharmaceutical market could represent a $411.2 billion opportunity for drug manufacturers, a 20.5% CAGR. Various factors such as low cost of the products, significantly less or no side effects of herbal medicine, rising usage by the global population, and ease of availability will further aid in the market growth over the forecast period.  

As a result of the factors, Africa is on track to become the fastest growing pharmaceutical market in the world over the next decade.  

  

APIQUEST USA intends to take advantage of that opportunity to bring to the US market life-saving drugs, whether natural or synthesized, to help save precious American lives.  

  

 

Contacts

Location:

 

+1 240 200 4404

APIQuestUSA Inc

651 N. Broad St, Middletown

DE 19709

USA

Info@apiquestusa.com

 

 

Get API key from Google and insert it to plugin properties to enable maps on your website.
Name  
Email  
Message  

Press Release

 

FOR IMMEDIATE RELEASE
04/03/2021 Media Contact:
                                                                                                                        Michael Thompson
                                                                                                                      (301) 318-0764 Phone
                                                                                                                      (301) 808-6960 Fax
                                                                                                             mthompson@apiquestusa.com
 

 

                                        APIQUEST-USA Explores Launch of New
                                      Remedy For COVID-19 In the United States 

   

Washington, District of Columbia: APIQUEST-USA, a US registered company, is excited to
announce its intent to launch several clinical trials to study the efficacy and safety of Apivirine for the
prevention and treatment of the COVID 19 infection. Apivirine is a plant-based product extracted
from the Dichrostachys Glomerate plant, one of the most widely used medicinal plants in tropical
regions worldwide. It is particularly important in tropical Africa and India, and all parts of the plant are
used except inflorescences.


Apivirine has been used for nearly 20 years for the treatment of HIV/AIDS in Africa and has recently
shown encouraging signs in the treatment against COVID 19 in Burkina Faso, Africa, where a recent
clinical trial took place at the University of Burkina Faso. It is now being evaluated as a covid-19
remedy for active clinical trials in South Africa, Ghana, and Canada. According to Professor Martial
Ouédraogo, the study at the University of Burkina Faso " demonstrated the efficacy and safety of
Apivirine in the curative treatment of covid-19 in 45 patients in that they have all been cured after an
early improvement in their health.”


The World Health Organization (WHO) recognizes that traditional medicine has many benefits and
welcomes innovation to new therapies to search for potential treatments for COVID-19. While there is
currently, scientific research taking place at Toledo University in Ohio, it is in this vein that APIQUEST

further seeks to collaborate with U.S. institutions to establish the efficacy and safety of Apivirine
through rigorous clinical trials.


APIQUEST CEO Mbaye Diagne says, “As an over-the-counter nutraceutical that comes in syrup for
children and gel capsule form, we believe we have an additional tool besides the promising vaccines
to combat COVID-19. We have submitted requests to the U.S. government (i.e., The U.S. Army) for
clinical trials. Getting the results is critical to speeding up the approval process. The numbers of
United States citizens affected by this disease is alarming compared to other countries around the
world, and we want to make a difference from a humanitarian perspective.”

 

–APIQUEST-USA is a minority-owned company incorporated in the State of Delaware.
The company is focused on solutions to eradicate the deadly COVID-19 pandemic and
ensure that what lies beyond the pandemic will be better than what was before... better for
business, better for the environment, and better for members of society. To date, the virus
has killed more than 600,000 in the United States and more than 3,900,000 worldwide.
APIQUEST-USA has signed an exclusive agreement with Dr. Valentin Agon, a world-
renowned African doctor and researcher, a graduate of UQAR University of Quebec in
Rimouski in Canada, owner of APIVIRINE. This natural antiviral drug has been shown to
be useful with many deadly viruses, including HIV-AIDS. To this end, Apiquest USA is moving

ahead with various partners to prove the efficacy of Apivirine as a treatment of Covid-19.